Sarepta must provide additional data to FDA

The Food and Drug Administration requested additional data from Sarepta Therapeutics Inc. (Nasdaq: SRPT) for its New Drug Application to treat Duchenne muscular dystrophy with eteplirsen. The stock price plummeted $7.69 to $15.87.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.